Skip Navigation

Evidence-Based Toxicology Collaboration

Tox21 data analysis work group

With the availability of data generated in a multi-year US EPA ToxCastTM (ToxCast) and a federal collaborative program between US EPA, FDA, NIH, NTP at NIEHS called Toxicology in the 21st Century, or Tox21TM (Tox21) there is a need to address if and how this type of mechanistic data can be used in the risk assessment process of chemicals.  EBTC has established a working group that will study how the mechanistic data from ToxCast and Tox21 can be used in safety assessment. The group is currently running a pilot studyIn a pilot study, an existing ToxCast data set will be used. The compounds in the set are all drugs that have a well-documented liver and/or heart organ toxicity. There is an equal number of negative controls, drugs, which do not illicit toxicity. The Working Group is now developing a protocol for a systematic scoping review for the most significant adverse effects in the liver and heart as observed in experimental animals after treatment with these 10 drugs. The observed adverse effect (AE) profile in experimental animals together with the AE profile as observed in patients will be compared with the pathways signatures based on ToxCast and Tox21 data.   

Work Group members:

Hubert Dirven, Co-chair
Norwegian Institute of Public Health, Oslo, Norway

Thomas Hartung, Co-chair
Center for Alternatives to Animal Testing, Johns Hopkins School of Public Health 

Kris Thayer
Office of Health Assessment and Translation, NIEHS, Research Triangle Park, NC, USA

Carl Westmoreland
Director of Science and Technology, Unilever, Bedford, UK

Richard Judson
US EPA National Center for Computational Toxicology, Research Triangle Park, NC, USA

Daniele Wikoff
ToxStrategies, Austin, Texas, USA

Rodger Curren
Institute for In Vitro Sciences, Gaithersburg, MD, USA

Rob Wright
Johns Hopkins Univeristy, Baltimore, MD

If you are interested in more information or to get involved, please contact us!